Role of antihistamines in ocular allergy

Bielory, Leonard

doi:10.1016/s0002-9343(02)01435-3

Cited by 22 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of antihistamines on dry eye has been unanimously recognized by scholars all over the world and this study got the same conclusion. The finding in Wisconsin [41] showed that dry eye could be related to the use of antihistamines that have anticholinergic properties owing to high muscarinic receptor binding. Systemic antihistamines, including old and newer generations, have been shown to potentially cause clinically meaningful damage to the ocular surface as a result of anti-muscarinic activity on the M3 receptors that results in a decrease in both aqueous and mucin tear [42].…”

Section: Discussionmentioning

confidence: 99%

Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China

Deng

Wang

et al. 2019

J Transl Med

View full text Add to dashboard Cite

Background Although previous prevalence studies of DED were reported from some countries worldwide, national data are unavailable in China. We aimed to conduct an up-to-date national survey on the prevalence of DED in China and find out the potential risk factors including air pollutant. Methods 23,922 eligible outpatients were recruited from ophthalmic clinics of 32 cities in China in 2013 by registration orders. The patients’ demographic characteristics, history of keratorefractive surgery, diseases and medication history were collected and the daily air pollutant data in 2013. Multivariate logistic analysis was performed to identify the potential risk factors associated with DED. The association between related factors and dry eye diseases subtypes evaluated as p value and odds ratios (OR) with 95% confidence intervals (CI). Results Among 23,922 outpatients, the prevalence of DED was 61.57%, and that of the male patients was 57.64% and of the female was 65.32% (P < 0.0001). Multivariate logistic regression suggested that the possible risk factors for DED included: female, older age, history of keratorefractive surgery, presence of arthritis, thyroid diseases, and antihistamine, diuretic, duodenal ulcer drugs, diazepam. Air pollutants including O 3 , PM 2.5 , and SO 2 were also identified as the risk factors. Conclusion The prevalence of DED among ophthalmic outpatients in China was considerably high. Age, gender, history of keratorefractive surgery, diseases, medication history, and air pollutants were associated with DED prevalence.

show abstract

Section: Discussionmentioning

confidence: 99%

Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China

Deng

Wang

et al. 2019

J Transl Med

View full text Add to dashboard Cite

show abstract

“…However, review of the literature indicates that intranasal corticosteroids may be as effective as, or even superior to, oral antihistamines in relieving ocular symptoms of AR [9,10,11,12,13]. According to a meta-analysis of randomized, controlled trials published between 1966 and 1997 comparing oral antihistamines and intranasal corticosteroids, only 2 of 11 studies in which ocular symptoms were evaluated found antihistamines to be superior to intranasal corticosteroids [10].…”

Section: Introductionmentioning

confidence: 99%

Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis

Anolik

Nathan

Schenkel³

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Burdensome symptoms of allergic rhinitis (AR) include nasal and ocular symptoms such as itching, tearing and redness. Intranasal corticosteroids are efficacious in the treatment of nasal symptoms of AR. Objective: It was the aim of this study to determine the efficacy of the intranasal corticosteroid mometasone furoate nasal spray (MFNS) in relieving ocular symptoms associated with seasonal AR (SAR). Methods: Ocular symptom data were analyzed for subjects ≧12 years of age, randomized to MFNS 200 µg q.d. (n = 176) or placebo (n = 177) in a placebo-controlled, double-blind clinical trial. Post hoc efficacy analysis assessed the mean change from baseline in subject-reported total ocular symptom scores (TOSS) averaged over the treatment period. Results: Mean baseline TOSS was 4.91 for the MFNS group and comparable (5.05) for the placebo group – combined average for individual symptoms such as itching, tearing and redness ranged from 0 (no symptoms) to 9 (all symptoms, severe). Mean change from baseline in TOSS averaged over days 1–15 was –1.42 for the MFNS group and –0.94 for the placebo group (p = 0.02), for an observed treatment difference of 0.49 (statistical data rounded to 2 decimal positions). Improvement in individual symptoms (eye itching, tearing and redness) contributed to this treatment effect; the greatest improvement occurred with tearing, which decreased –0.52 from the baseline score 1.59 in the MFNS group and –0.31 from 1.67 in those receiving placebo (p < 0.01), for an observed treatment difference of 0.21. Treatment with MFNS was safe and well tolerated. Conclusion: MFNS is effective in reducing ocular symptoms of SAR, in addition to its established efficacy in reducing nasal symptoms of SAR.

show abstract

“…Topical agents, such as eye drops, typically provide faster relief of ocular symptoms than oral agents, and, logically, combination therapy with a topical and oral agent has been found to be superior to oral alone [33][34][35]. The topical ocular agents azelastine and olopatadine have exhibited both an early-phase symptomatic relief in patients with allergic conjunctivitis, using a multiple mechanistic approach of antihistamine/mast cellstabilization, and an anti-inflammatory response.…”

Section: Discussionmentioning

confidence: 99%

Ocular allergy treatment comparisons: Azelastine and olopatadine

Bielory

Buddiga

Bigelson

2004

Curr Allergy Asthma Rep

Self Cite

View full text Add to dashboard Cite

Azelastine hydrochloride 0.05% and olopatadine hydrochloride 0.1% are topical ocular allergy treatments that have demonstrated multiple pharmacologic actions, including antihistamine, mast cell stabilization, and inhibition of proinflammatory mediators. In this article, the mechanisms of action, efficacy, and tolerability of these two agents on ocular signs and symptoms are examined. By studying the various target sites of drug action, an enhanced clinical response algorithm of these topical ocular agents can be implemented to maximize the response for patients suffering from ocular allergy.

show abstract

Role of antihistamines in ocular allergy

Cited by 22 publications

References 23 publications

Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China

Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China

Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis

Ocular allergy treatment comparisons: Azelastine and olopatadine

Contact Info

Product

Resources

About